We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+4.24%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.94B
AUM Growth
-$224M
(-2.7%)
Cap. Flow
-$1.98B
Cap. Flow
% of AUM
-24.95%
Top 10 Holdings %
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$30.4M |
| 2 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$19.4M |
| 3 |
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
|
+$16.5M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$15.8M |
| 5 |
XNPT
XENOPORT, INC.
XNPT
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITMN
INTERMUNE INC
ITMN
|
+$209M |
| 2 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$46.2M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$32.8M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$18.1M |
| 5 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.74% |
| 2 | Healthcare | 44.26% |
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q3 2014 Portfolio in Review
As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Baker Bros. Advisors withdrew a net $1.98B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 55% a quarter earlier, followed by Healthcare.
Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.
- Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
- Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
- Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
- Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
- Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
- Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
- Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.
Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.